Data are provided by many contributors through the the WHO Clinical data platform and are not necessarily representative. To become a contributor, please see the terms of use and register here.

Total cases

77

Total facilities

2

Total PLWH

10

Women

36.4%

Children below 5

11.7%

Total deaths

1

The map below is just a proof of concept. Can be adjusted once/if we have data at the regional level.

Geospatial distribution
Cases reported
Mirror plots
Chronic conditions
Variable Sample size Prevalence pct Frequency
HIV (Human Immunodeficiency Virus) 77 13.0% 10 / 77
Hypertension 77 5.2% 4 / 77
Current new STI (Sexually Transmitted Infection) diagnosis? 77 2.6% 2 / 77
Syphilis 2 100.0% 2 / 2
Chronic heart disease 77 0.0% 0 / 77
Chronic lung disease 77 0.0% 0 / 77
Chronic kidney disease 77 0.0% 0 / 77
Chronic liver disease 77 0.0% 0 / 77
Chronic neurologic condition 77 0.0% 0 / 77
Current alcohol use disorder 77 0.0% 0 / 77
Previous COVID-19 infection 77 0.0% 0 / 77
Diabetes 77 0.0% 0 / 77
Currently smokes tobacco 77 0.0% 0 / 77
Skin Conditions 77 0.0% 0 / 77
Tuberculosis (previous) 77 0.0% 0 / 77
Tuberculosis (active) 77 0.0% 0 / 77
Asplenia 77 0.0% 0 / 77
Cancer 77 0.0% 0 / 77
Immunosuppressive condition 77 0.0% 0 / 77
N. gonorrhoeae 2 0.0% 0 / 2
HSV 2 0.0% 0 / 2
Chlamydia trachomatis 2 0.0% 0 / 2
HPV 2 0.0% 0 / 2
AIDS - defining illness 9 0.0% 0 / 9

Source: WHO
Complications
Variable Sample size Prevalence pct Frequency
Cellulitis 73 20.5% 15 / 73
Bacteraemia 73 12.3% 9 / 73
Abscess 73 5.5% 4 / 73
Anaemia 73 4.1% 3 / 73
Bacterial Pneumonia 73 4.1% 3 / 73
Sepsis 73 2.7% 2 / 73
Ocular Complications 73 2.7% 2 / 73
Shock 73 1.4% 1 / 73
Encephalitis / Meningitis 73 1.4% 1 / 73
Bleeding Disorder 73 1.4% 1 / 73
Cardiac Arrest 73 1.4% 1 / 73
Cardiac Arrhythmia 73 1.4% 1 / 73
Cardiomyopathy 73 1.4% 1 / 73
Myocarditis / Pericarditis 73 1.4% 1 / 73
Viral Pneumonia / Pneumonitis 73 1.4% 1 / 73
Acute Respiratory Distress Syndrome (Ards) 73 1.4% 1 / 73
Urinary Retention 73 1.4% 1 / 73
Seizure 73 0.0% 0 / 73
Stroke / Cerebrovascular Accident 73 0.0% 0 / 73
Guillain-Barré Syndrome 73 0.0% 0 / 73
Acute Renal Injury / Acute Renal Failure 73 0.0% 0 / 73
Pancreatitis 73 0.0% 0 / 73
Liver Dysfunction 73 0.0% 0 / 73
Necrotizing Infection 73 0.0% 0 / 73
Proctitis 73 0.0% 0 / 73
Rectal Urgency 73 0.0% 0 / 73
Rectal Pain 73 0.0% 0 / 73

Source: WHO
Body map of lesions at admission
Prevalence of lesions at admission
Variable Sample size Prevalence pct Frequency
Upper limb 76 82.9% 63/76
Chest and abdomen 76 80.3% 61/76
Head and neck 76 77.6% 59/76
Lower limb 76 73.7% 56/76
Back 76 72.4% 55/76
Genitals 76 48.7% 37/76
Mouth 75 26.7% 20/75

Source: WHO
Type of lesions
Variable Sample size Prevalence pct Frequency
Papule 77 76.6% 59/77
Macule 77 57.1% 44/77
Small pustule 77 37.7% 29/77
Umbilicated pustule 77 33.8% 26/77
Crusting of a mature lesion 77 33.8% 26/77
Early vesicle 77 28.6% 22/77
Ulcerated lesion 77 27.3% 21/77
Partially removed scab 77 18.2% 14/77

Source: WHO
Reported symptoms
Symptoms at admission
Variable Sample size Prevalence pct Frequency
Fever 76 84.2% 64 / 76
Headache 77 66.2% 51 / 77
Pruritis/itching 76 63.2% 48 / 76
Muscle pain or aching 77 59.7% 46 / 77
Fatigue or malaise 77 58.4% 45 / 77
Sore throat 77 40.3% 31 / 77
Joint pain or aching 77 31.2% 24 / 77
Pain in mouth 77 27.3% 21 / 77
Swallowing problem 77 27.3% 21 / 77
Painful swallow 21 95.2% 20 / 21
Urinary symptoms 77 22.1% 17 / 77
Pain with urination 17 100.0% 17 / 17
Psychologic disturbance 77 18.2% 14 / 77
Dizziness 77 14.3% 11 / 77
Nausea 77 7.8% 6 / 77
Difficult swallow 21 23.8% 5 / 21
Chest pain 77 5.2% 4 / 77
Decrease urine output 16 25.0% 4 / 16
Ocular symptoms (pain, redness, visual loss) 77 3.9% 3 / 77
Vomiting 77 3.9% 3 / 77
Red eye(s) 3 100.0% 3 / 3
Diarrhoea 77 2.6% 2 / 77
Any rectal symptom 77 2.6% 2 / 77
Urethral discharge 17 11.8% 2 / 17
Rectal pain 2 100.0% 2 / 2
Eye pain 3 33.3% 1 / 3
Other 3 33.3% 1 / 3
Proctitis 77 0.0% 0 / 77
Rectal discharge 2 0.0% 0 / 2
Rectal urgency/tenesmus 2 0.0% 0 / 2
Visual disturbance 3 0.0% 0 / 3
...with blood 3 0.0% 0 / 3

Source: WHO
Symptoms at discharge
Variable Sample size Prevalence pct Frequency
Sore throat 73 1.4% 1 / 73
Fever 72 0.0% 0 / 72
Pruritis/itching 71 0.0% 0 / 71
Muscle pain or aching 73 0.0% 0 / 73
Headache 73 0.0% 0 / 73
Ocular symptoms (pain, redness, visual loss) 73 0.0% 0 / 73
Fatigue or malaise 73 0.0% 0 / 73
Pain in mouth 73 0.0% 0 / 73
Nausea 73 0.0% 0 / 73
Vomiting 73 0.0% 0 / 73
Diarrhoea 73 0.0% 0 / 73
Any rectal symptom 73 0.0% 0 / 73
Swallowing problem 73 0.0% 0 / 73
Chest pain 73 0.0% 0 / 73
Joint pain or aching 73 0.0% 0 / 73
Proctitis 73 0.0% 0 / 73
Dizziness 73 0.0% 0 / 73
Psychologic disturbance 73 0.0% 0 / 73
Urinary symptoms 73 0.0% 0 / 73

Source: WHO
Variable

Person with HIV
N = 10

Person without HIV
N = 62

Unknown
N = 5

 p-value 1
age, Median (Q1, Q3) 11.00 (8.00, 12.00) 8.00 (5.00, 9.00) 10.00 (9.00, 10.00) 0.008
    Missing/Unknown 1 0 0
Sex at birth, n (%)


0.3
    Male 5 (50%) 40 (65%) 3 (60%)
    Female 4 (40%) 22 (35%) 2 (40%)
    Intersex 0 (0%) 0 (0%) 0 (0%)
    Unknown 1 (10%) 0 (0%) 0 (0%)
Race, n (%)


>0.9
    African/Black 9 (90%) 57 (92%) 5 (100%)
    Arab 0 (0%) 0 (0%) 0 (0%)
    Asian 0 (0%) 0 (0%) 0 (0%)
    Hispanic/Latino 0 (0%) 0 (0%) 0 (0%)
    Mixed Race 0 (0%) 0 (0%) 0 (0%)
    White 0 (0%) 0 (0%) 0 (0%)
    Unknown 1 (10%) 5 (8.1%) 0 (0%)
    Other 0 (0%) 0 (0%) 0 (0%)
health care worker, n (%)


0.4
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 9 (90%) 61 (98%) 5 (100%)
    Unknown 1 (10%) 1 (1.6%) 0 (0%)
Laboratory worker, n (%)


0.6
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 9 (90%) 59 (95%) 5 (100%)
    Unknown 1 (10%) 3 (4.8%) 0 (0%)
Sex worker, n (%)


0.026
    Yes 3 (30%) 2 (3.2%) 1 (20%)
    No 6 (60%) 56 (90%) 4 (80%)
    Unknown 1 (10%) 4 (6.5%) 0 (0%)
currently pregnant or was pregnant in the last 6 weeks?, n (%)


>0.9
    Yes 0 (0%) 1 (4.5%) 0 (0%)
    No 4 (100%) 21 (95%) 2 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 6 40 3
Breastfeeding, n (%)



    Yes 0 (NA%) 0 (NA%) 0 (NA%)
    No 0 (NA%) 0 (NA%) 0 (NA%)
    Unknown 0 (NA%) 0 (NA%) 0 (NA%)
    Missing/Unknown 10 62 5
1

Kruskal-Wallis rank sum test; Fisher’s exact test
Variable

Person with HIV
N = 10

Person without HIV
N = 62

Unknown
N = 5

 p-value 1
ever hospitalized, n (%)


>0.9
    Yes 7 (88%) 49 (82%) 4 (100%)
    No 1 (13%) 11 (18%) 0 (0%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 2 2 1
Length of hospitalization, Median (Q1, Q3) 12 (5, 15) 6 (5, 12) 7 (5, 8) 0.3
    Missing/Unknown 3 13 1
Escalation of care, n (%)


0.031
    Yes 1 (14%) 0 (0%) 1 (25%)
    No 6 (86%) 49 (100%) 3 (75%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 3 13 1
supplemental oxygen, n (%)


0.019
    Yes 1 (14%) 0 (0%) 0 (0%)
    No 6 (86%) 49 (100%) 3 (75%)
    Unknown 0 (0%) 0 (0%) 1 (25%)
    Missing/Unknown 3 13 1
receive nasogastric fluids, n (%)


>0.9
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 9 (100%) 60 (100%) 4 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 1 2 1
receive IV fluids during course monkeypox infection, n (%)


0.005
    Yes 2 (22%) 2 (3.3%) 2 (50%)
    No 7 (78%) 58 (97%) 2 (50%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 1 2 1
receive analgesia for pain management, n (%)


0.006
    Yes 6 (67%) 20 (33%) 4 (100%)
    No 3 (33%) 40 (67%) 0 (0%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 1 2 1
receive antibiotics during course monkeypox infection, n (%)


0.4
    Yes 7 (78%) 55 (92%) 4 (100%)
    No 2 (22%) 5 (8.3%) 0 (0%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 1 2 1
receive antifungals during course monkeypox infection, n (%)


>0.9
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 9 (100%) 60 (100%) 4 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 1 2 1
experimental antiviral during course monkeypox infection, n (%)


>0.9
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 8 (100%) 60 (100%) 4 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 2 2 1
1

Fisher’s exact test; Kruskal-Wallis rank sum test
Variable

Person with HIV
N = 10

Person without HIV
N = 62

Unknown
N = 5

 p-value 1
History of tetanus vaccination, n (%)


0.5
    Yes 0 (0%) 6 (9.7%) 0 (0%)
    No 2 (20%) 21 (34%) 3 (60%)
    Unknown 8 (80%) 35 (56%) 2 (40%)
History of smallpox vaccination before 1980, n (%)


0.5
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 7 (70%) 52 (84%) 5 (100%)
    Unknown 3 (30%) 10 (16%) 0 (0%)
History of smallpox or monkeypox vaccination in past year, n (%)


0.7
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 9 (90%) 58 (94%) 5 (100%)
    Unknown 1 (10%) 4 (6.5%) 0 (0%)
Number of vaccines received, Median (Q1, Q3) NA (NA, NA) NA (NA, NA) NA (NA, NA)
    Missing/Unknown 10 62 5
1

Fisher’s exact test
Variable

Person with HIV
N = 10

Person without HIV
N = 62

Unknown
N = 5

 p-value 1
New diagnosis of HIV, n (%)


0.034
    Yes 0 (0%) 1 (1.7%) 1 (25%)
    No 7 (100%) 58 (97%) 2 (50%)
    Unknown 0 (0%) 1 (1.7%) 1 (25%)
    Missing/Unknown 3 2 1
Current new STI (Sexually Transmitted Infection) diagnosis, n (%)



    Yes 0 (0%) 0 (NA%) 0 (NA%)
    No 2 (100%) 0 (NA%) 0 (NA%)
    Unknown 0 (0%) 0 (NA%) 0 (NA%)
    Missing/Unknown 8 62 5
Immunosuppressive condition, n (%)


0.003
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 10 (100%) 62 (100%) 3 (60%)
    Unknown 0 (0%) 0 (0%) 2 (40%)
Most recent CD4, Median (Q1, Q3) 98 (98, 98) NA (NA, NA) NA (NA, NA)
    Missing/Unknown 1 62 5
Viral load, n (%)



    Detectable 0 (0%) 0 (NA%) 0 (NA%)
    Undetectable 3 (33%) 0 (NA%) 0 (NA%)
    Unknown 6 (67%) 0 (NA%) 0 (NA%)
    Missing/Unknown 1 62 5
AIDS - defining illness, n (%)



    Yes 0 (0%) 0 (NA%) 0 (NA%)
    No 9 (100%) 0 (NA%) 0 (NA%)
    Unknown 0 (0%) 0 (NA%) 0 (NA%)
    Missing/Unknown 1 62 5
1

Fisher’s exact test
Skin lesions by HIV status
Complications by HIV status
Exposure distribution
Variable Sample size Prevalence pct Frequency
Sexually active within ≤ 21 days prior to symptom onset? 77 44.2% 34/77
Number of heterosexual partners in the last three months 33 78.8% 26/33
Any known link to probable or confirmed case of monkeypox within ≤ 21 days prior to symptom onset? 77 9.1% 7/77
International travel within ≤ 21 days prior to symptom onset? 77 3.9% 3/77
Contact with possible animal source within ≤ 21 days prior to symptom onset? 77 0.0% 0/77
Did the patient receive experimental antiviral during course monkeypox infection? 72 0.0% 0/72

Source: WHO
Variable N = 77
Mpox clade known:, n (%)
    Yes 0 (0%)
    No 73 (100%)
    Unknown 0 (0%)
    Missing/Unknown 4
Mpox clade, n (%)
    Ia 0 (NA%)
    Ib 0 (NA%)
    IIa 0 (NA%)
    IIb 0 (NA%)
    Missing/Unknown 77
Monkeypox PCR, n (%)
    Yes 71 (97%)
    No 2 (2.7%)
    Unknown 0 (0%)
    Missing/Unknown 4
Monkeypox Result, n (%)
    Positive 35 (49%)
    Negative 34 (48%)
    Indeterminate 0 (0%)
    Unknown 2 (2.8%)
    Missing/Unknown 6
Monkeypox viral culture, n (%)
    Yes 0 (0%)
    No 73 (100%)
    Unknown 0 (0%)
    Missing/Unknown 4
Monkeypox viral culture Result, n (%)
    Positive 0 (NA%)
    Negative 0 (NA%)
    Indeterminate 0 (NA%)
    Unknown 0 (NA%)
    Missing/Unknown 77
Variable N = 77
Orthopoxvirus PCR, n (%)
    Yes 0 (0%)
    No 73 (100%)
    Unknown 0 (0%)
    Missing/Unknown 4
Orthopoxvirus Result, n (%)
    Positive 0 (NA%)
    Negative 0 (NA%)
    Indeterminate 0 (NA%)
    Unknown 0 (NA%)
    Missing/Unknown 77
Variable N = 77
Malaria result, n (%)
    Positive 0 (0%)
    Negative 3 (100%)
    Indeterminate 0 (0%)
    Unknown 0 (0%)
    Missing/Unknown 74
Syphilis result, n (%)
    Positive 1 (50%)
    Negative 1 (50%)
    Indeterminate 0 (0%)
    Unknown 0 (0%)
    Missing/Unknown 75
Variable

Baseline visit
N = 77
Hemoglobin, Median (Q1, Q3) 13.00 (11.10, 15.30)
WCC total, Median (Q1, Q3) 7.0 (6.3, 11.1)
Platelets, Median (Q1, Q3) 252 (156, 319)
PT, Median (Q1, Q3) NA (NA, NA)
APTT, Median (Q1, Q3) NA (NA, NA)
Total Bilirubin, Median (Q1, Q3) NA (NA, NA)
ALT, Median (Q1, Q3) NA (NA, NA)
AST, Median (Q1, Q3) NA (NA, NA)
Na+, Median (Q1, Q3) NA (NA, NA)
K+, Median (Q1, Q3) NA (NA, NA)
Urea/BUN, Median (Q1, Q3) NA (NA, NA)
Creatinine, Median (Q1, Q3) NA (NA, NA)
Glucose, Median (Q1, Q3) NA (NA, NA)
Lactate, Median (Q1, Q3) NA (NA, NA)
CRP, Median (Q1, Q3) NA (NA, NA)
Creatine kinase, Median (Q1, Q3) NA (NA, NA)
Variable

During infection management
N = 158
Hemoglobin, Median (Q1, Q3) 12.80 (11.10, 15.90)
WCC total, Median (Q1, Q3) 6.9 (5.1, 10.4)
Platelets, Median (Q1, Q3) 253 (156, 332)
PT, Median (Q1, Q3) NA (NA, NA)
APTT, Median (Q1, Q3) NA (NA, NA)
Total Bilirubin, Median (Q1, Q3) NA (NA, NA)
ALT, Median (Q1, Q3) NA (NA, NA)
AST, Median (Q1, Q3) NA (NA, NA)
Na+, Median (Q1, Q3) NA (NA, NA)
K+, Median (Q1, Q3) NA (NA, NA)
Urea/BUN, Median (Q1, Q3) NA (NA, NA)
Creatinine, Median (Q1, Q3) NA (NA, NA)
Glucose, Median (Q1, Q3) NA (NA, NA)
Lactate, Median (Q1, Q3) NA (NA, NA)
CRP, Median (Q1, Q3) NA (NA, NA)
Creatine kinase, Median (Q1, Q3) NA (NA, NA)
Variables Lab measures distribution
N Mean Median Min Max Distribution
Baseline visit
Hemoglobin 17.00 13.22 13.00 6.30 18.00
Platelets 17.00 264.88 252.00 71.00 731.00
WCC total 16.00 8.97 6.95 3.00 29.00
Outcomes